Проноран в лечении когнитивных расстройств

1. Варакин Ю.Я. Профилактика нарушений мозгового кровообращения. Очерки ангионеврологии. Ред. З.А.Суслина. М., 2005.
2. Дамулин И.В. Болезнь Альцгеймера и сосудистая деменция. Под ред. Н.Н.Яхно. М., 2002.
3. Дамулин И.В. Рус. мед. журн. 2006; 9: 658–64.
4. Дробижев М.Ю. Распространенность психических расстройств в общемедицинской сети и потребность в психофармакотерапии. Психиат. и психофармакотер. 2002; 5: 175–80.
5. Захаров В.В., Дамулин И.В., Яхно Н.Н. Медикаментозная терапия деменций. Клин. фармакол. и тер. 1994; 3 (4): 69–75.
6. Захаров В.В., Яхно Н.Н. Рус. мед. журн. 2004; 10: 573–6.
7. Захаров В.В., Локшина А.Б. Применение препарата проноран (пирибедил) при легких когнитивных расстройствах у пожилых больных с дисциркуляторной энцефалопатией. Неврол. журн. 2004; 2: 30–5.
8. Захаров В.В. Когнитивные нарушения в неврологической практике. Трудн. пациент. 2005; 5.
9. Захаров В.В. Когнитивные нарушения. Возрастные нарушения памяти и внимания. Consilium Medicum 2005; 7 (8).
10. Захаров В.В. Всероссийская программа исследований эпидемиологии и терапии когнитивных расстройств в пожилом возрасте («Прометей»). Неврол. журн. 2006; 2: 27–32.
11. Кадыков А.С., Шахпаронова Н.В. Consilium Medicum 2002; 2: 71–7.
12. Климов Л.В., Парфенов В.А. Неврол. журн. 2006; 11 (Приложение №1): 53–7. Ballard C, Rowan E, Stephens S et al. Stroke 2003; 34: 2440–4.
13. Левин О.С. Consilum Medicum 2006; 8: 106–12.
14. Локшина А.Б., Захаров В.В. Неврол. журн. 2006; 11 (Приложение 1): 57–64.
15. Лурия А.Р. Высшие корковые функции человека. М.: изд-во МГУ. 1969.
16. Лурия А.Р. Мозг человека и психические процессы. М.: Педагогика, 1970; 2: 496.
17. Лурия А.Р. Основы нейропсихологии. М.: изд-во МГУ. 1973.
18. Международная статистическая классификация болезней и проблем, связанных со здоровьем. Десятый пересмотр. (МКБ-10). Женева, ВОЗ. 1995.
19. Федорова Н.В., Артемьева Е.Г. Применение пронорана – современного агониста дофаминовых рецепторов в лечении болезни Паркинсона (информационное письмо). М., 2003; 20.
20. Яхно Н.Н., Левин О.С., Дамулин И.В. Сопоставление клинических и МРТ-данных при дисциркуляторной энцефалопатии. Сообщение 2: Когнитивные нарушения. Неврол. журн. 2001; 6 (3): 10–19.
21. Яхно Н.Н., Захаров В.В., Локшина А.Б. Синдром умеренных когнитивных нарушений при дисциркуляторной энцефалопатии. Журн. неврол. и психиат. 2005; 105 (2): 13–7.
22. Яхно Н.Н. Неврол. журн. 2006; 11 (Приложение 1): 4–12.
23. Ahmadzadeh GH, Farhat A, Soltani D. Prevalence of cognitive dysfunction in old patients admitted in emergency room. Neurodegenerative Dis 2007; 4 (1): 124.
24. Ainiala H, Loukkola J, Peltola J et al. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 2001; 57 (3): 496–500.
25. Aisen PS, Schafer KA, Grundman M et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003; 289: 2819–26.
26. Alexander EL, Ranzenbach MR, Kumar AJ et al. Anti-Ro(SS-A) autoantibodies in central, nervous system disease associated with Sj_gren's syndrome (CNS-SS): clinical, neuroimaging, and angiographic correlates. Neurology 1994; 44: 899–908.
27. American Psychiatry Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Ed. Washington: American Psychiatry Association. 1994.
28. Asherson RA, Mercey D, Phillips G et al. Recurrent stroke and multi-infarct dementia in systemic lupus erythematosus: association with antiphospholipid antibodies. Ann Rheum Dis 1987; 46: 605–11.
29. Assaad-Khalil S, Abou-Seif M, Abou-Seif S et al. Neurological involvement in Behcet's disease: clinical genetic and computed tomographic study. In: Behcet's Disease 1993; 409–14.
30. Ballard CG, O'Brien JT, Reichelt K et al. Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double-blind, placebo-controlled trial with Melissa. J Clin Psychiat 2002; 63: 553–8.
31. Ballard C, Rowan E, Stephens S et al. Stroke 2003; 34: 2440–4.
32. Bartoli G, Wichrowska E. Controlled clinical trial of piribedil in the treatment of cerebrovascular insufficiency. La Clin Ter 1976; 78 (2): 141–51.
33. Bille J, Bukiwsky JV, De Ferron A et al Decline cerebral et therapeutique: une etude clinique multicenrique de Trivastal 50 retard en Neuro-Geriatrie. Psych Med 1986; 18: 609–26.
34. Bohlega S, Al Kawi MS, Omer S et al. Neuro-Behcet's: clinical syndromes and prognosis. In: Behcet's Disease 1993; 429–34.
35. Bornstein N. Post stroke dementia. V international congress on Vascular Dementia. Abstracts 2007; 53–4.
36. Brey L, Holliday SL, Saklad AR et al. Neuropsychiatric syndromes in lupus. Prevalence using standardized definitions. Neurology 2002; 58: 1214–20.
37. Butkovic-Soldo S, Hegedus I, Tomic S, Juric S. Epidemioilogy and comorbidity od dementia – hospital based study. V international congress on Vascular Dementia. Abstracts 2007; 67.
38. Cagnotto A, Parotti L, Mennini T. In vitro affinity of piribedil for dopamine D3 receptor subtypes, an autoradiographic study. Eur J Pharmacol 1996; 10: 63–7.
39. Caselli RJ, Scheithauer BW et al. The treatable dementia of Sj_gren's syndrome. Ann Neurol 1991; 30: 98–101.
40. Corradino et al. Trivastal retard 50 in everyday medical practice. Its value in the treatment of dizziness, tinnitus and memory disorders. Trib Med 1988; 3: 39–42.
41. DeCarli. The role of cerebrovascular disease in dementia. Neurologist 2003; 9: 123–36.
42. de Leeuw FE, van Gijn J. Pract Neurol 2003; 3: 86–91.
43. Geroldi C, Ferrucci L, Bandinelli S et al. J Amer Ger Soc 2003; 51: 1064–71.
44. Golomb J, Kluger A, Garrard P, Ferris S. Clinician's manual on mild cognitive impairment. London: Science Press Ltd, 2001; 56.
45. Jennekens FGI, Kater L. The central nervous system in systemic lupus erythematosus. Part 2. Pathogenetic mechanisms of clinical syndromes: a literature investigation. Rheumatology 2002; 41: 619–30.
46. Jenner P. Piribedil induces low levels of dyskinesia in MPTP – treated common marmoset. Abstract of 52 Annual Meeting of the American Academy of Neurology. San Diego 2000.
47. Jonker C, Geerlings MI, Schmand B. Are memory predictive for dementia? A review of clinical and population-based studies. Int J Geriatr Psychiat 2000; 15: 983–91.
48. Jonsson L, Gustavsson A, Cortes F et al. International differences in Resource Use and Cost of Care in alzgeimer's disease: baseline data from the Ictus Study. Neurodegenerative Dis 2007; 4 (1): 122.
49. Isshi K, Hirohata S. Differential roles of the anti-ribosomal P antibody and anti-neuronal antibody in the pathogenesis of central nervous system involvement in systemic lupus erythematosus. Arthritis Rheum 1998; 41: 1819–27.
50. Kahvecioglu U, Цzkaynak S, Zadikoglu A et al. Efficacy of piribedil on age – related cognitive decline. Med J Akdeniz University Cilt 1995; 12 (1–3): 1300–779.
51. Kase CS, Wolf PA, Kelly-Hayes M et al. Intellectual decline after stroke: the Framingbam Study. Stroke 1998; 29 (4): 805–12.
52. Lai CK, Chi I, Kayser-Jones J. A randomized controlled trial jf a specific reminiscence approach to promote the well-being of nursing home residents with dementia. Int Psychogeriat 2004; 16: 33–49.
53. Larrabee GJ, Crook TM. Estimated prevalence of age associated memory impairment derived from standardized tests of memory function. Int Psychogeriat 1994; 6 (1): 95–104.
54. Lezak MD. Neuropsychology assessment. N.Y. University Press. 1983; 768.
55. Logiudice D, Waltrowicz W, Brown K et al. Do memory clinics improve the quality of life carers? A randomized pilot trial. Int J Geriatr Psychiat 1999; 14: 626–32.
56. Lopez Mongil R, Lopez Trigo JA, Castrodeza Sanz J et al. Epidemiology of cardiovascular disease and its risk factors in institutionalized patients with dementia. The RESYDEM study. V international congress on Vascular Dementia. Abstracts 2007; 117.
57. Lu PH, Masterman DA, Mulnard R et al. Effects of testosterone on cognition and moon in male patients with mild Alzheimer disease and healthy elderly men. Arch Neurol 2006; 63: 177–85.
58. Malinow KL, Molina R, Gordon B et al. Neuropsychiatric dysfunction in primary Sj_gren's syndrome. Ann Intern Med 1985; 103: 344–9.
59. Mauch E, Volk C, Kratzsch G et al. Neurological and neuropsychiatric dysfunction in primary Sj_gren's syndrome. Acta Neurol Scand 1994; 89: 31–5.
60. Menzin J, Lang K, Friedman M et al. The economic cost Alzheimer's disease and related dementias to the California Medical Program in 1995. Am J Geriatr Psychiat 1999; 7: 300–8.
61. Millan MJ, Cussac D, Milligan G et al. Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization. J Pharmacol Exp Ther 2001; 297 (3): 876–87.
62. Mok CC, To CH, Mak A. Neuropsychiatric damage in Southern Chinese patients with systemic lupus erythematosus. Medicine (Baltimore) 2006; 85 (4): 221–8.
63. Motomura S, Tabira T, Kuroiwa Y. A clinical comparative study of multiple sclerosis and Neuro-Behcet's syndrome. J Neurol Neurosurg Psychiat 1980; 43: 210–3.
64. Muller M, Tang MX, Schupf N et al. Metabolic syndrome and dementia risk in a multiethnic elderly cohort. V international congress on Vascular Dementia. Abstracts 2007; 117.
65. Nagaraia D, Jayashree S. Randomised study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment. Am J Psychiat 2001; 158 (9): 1517–9.
66. Ollat H. J Neurol 1992; 239: 13–6.
67. Pallis CF, Fudge BJ. The neurological complications of Behcet's syndrome. Arch Neurol Psychiat 1956; 74: 1–14.
68. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256: 183–94.
69. Pobjasvaara T, Erkinjuntti T, Ylikoski R et al. Clinical determinations of poststroke dementia. Stroke 1998; 29 (1): 75–81.
70. Politis AM, Vozzella S, Mayer LS et al. A randomized controlled clinical trial of activity therapy for apathy in patients with dementia residing in long-term care. Int J Geriatr Psychiat 2004; 19: 1087–94.
71. Potliri R, Natalwala A, Narendar P, Heun R. Diabetes mellitus and dementia – a putative link? V international congress on Vascular Dementia. Abstracts 2007; 114.
72. Purandare N. Cerebral emboli in genesis of dementia. V international congress on Vascular Dementia. Abstracts 2007; 64.
73. Robin C, Gonnaud PM, Durieu I et al. D_mence lupique progressive. Deux cas avec anticorps antiphospholipides ou non. Rev Neurol (Paris) 1995; 151: 699–707.
74. Rogers MP, Waterhouse E, Nagel JS et al. I-123 iofetamine SPECT scan in systemic lupus erythematosus patients with cognitive and other minor neuropsychiatric symptoms: a pilot study. Lupus 1992; 1 (4): 215–9.
75. Rogers SL, Doody RS, Mohs RC et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998; 158: 1021–31.
76. Sanna G, Bertolaccini ML, Cuadrado MJ et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 2003; 30 (5): 985–92.
77. Scholing WE. Controlled trial of trivasal retard 50 and comparision with trivasal 20 in the treatment of clinical and mental signs of neurovascular disease. Scienc Med 1977; 4: 4–8.
78. Scholing WE. A double-blind study using psychometric tests Trivastal versus a reference compound. Temp Medical 1982; 114.
79. Skoog I et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141–5.
80. Smith LA, Jackson MG, Bonhomme C et al. Transdermal administration of piribedil reverses MPTP-induced motor deficits in the common marmoset. Clin Neuropharmacol 2000; 23: 133–42.
81. Spector A, Thorgrimsen L, Woods B et al. Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: randomized controlled trial. Br J Psychiat 2003; 183: 248–54.
81. Teri L, McCurry SM, Logsdon R et al. Training community consultans to help family members improve dementia care: a randomized controlled trial. Gerontologist 2005; 45: 802–11.
83. The American College of Rheumatology nomenclature and care definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42: 599–608.
84. Winblad B, Palmer K, Kivipelto M et al. Mild cognitive impairment – Beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004; 256: 240–6.
85. Winbland B, Wimo A. Pharmacoeconomics in Alzheimer's disease. Neurodegenerative Dis 2007; 4 (1): 5.
86. Whitmer RA, Selby JV, Zhou J, Karter AJ. Hypoglycemia as a major risk factor for dementia in patients with type 2 diabetes. V international congress on Vascular Dementia. Abstracts 2007; 62.
87. Van Uffelen JG, Hopman-Rock M, Chin APM et al. Protocol for Project FACT: randomized controlled trial on the effect of a walking program and vitamin B supplementation on the rate of cognitive decline and psychosocial wellbeing in older adults with cognitive impairment [ISRCTN19227688]. BMC Geriat 2005; 5: 18.
88. Ziegler M, Caldas A, Del Signore et al. Efficacy of piribedil in acinetic-hypertonic Parcinsonian patients after 4-month combination treatment with L-Dopa. Parkinson Related Disord 2001; 7: 75.

Н.В.Пизова